Objective: The selective reporting of favorable outcomes has a serious influence on our evidence base. However, this problem has not yet been systematically investigated in the field of psychiatry. Our study aimed to evaluate registration and outcome reporting in randomized controlled trials (RCTs) of standard treatments for depression: cognitive behavioral therapy (CBT) or new-generation antidepressants (AD).
Introduction
The full reporting of research studies is of paramount importance for the correct interpretations of their results by the patients, clinicians, researchers and policy makers.
It is not only a scientific but also an ethical obligation of the medical profession, as stipulated in the Declaration of Helsinki: "Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports." Accumulated and accumulating evidence reveals, however, that the reality is far from this ideal. First, studies themselves can remain unpublished, unavailable and unknown (1, 2) . Study publication bias occurs when the publication of research results depends on their nature and direction (1, 3, 4) . More than two decades after the problem was first pointed out, 31% of the pre-approval trials of antidepressants were unpublished (5), as were 17% of antipsychotic trials (6) . Alarmingly enough, of all FDA-approved drugs in 1998-2000, less than 50% of the pre-approval trials were published even more than 5 years post-marketing (7). It is not surprising that most of the unpublished trials were negative in contradistinction to the published positive trials (5) . Second, when studies are actually published, their outcomes can be hidden, changed and/or "spun" for embellishment (8) . The influence of selective outcome reporting appears to be subtle but is arguably more far-reaching and serious than study publication bias per se (9, 10) .
In one of the landmark studies of outcome reporting bias, Chan et al. compared protocols of 102 randomized controlled trials (RCTs) with their published reports and showed that 62% (51/82) of trials had inconsistencies between primary outcomes in protocols and those in published reports (10) .
Academia has not remained passive and silent against these biases that seriously undermine its own credibility (11, 12) . First, trial registration has been proposed and is now mandated. The International Committee of Medical Journal Editors (ICMJE) has advocated a policy that requires clinical trials starting after July 2005 to be registered before the enrollment of the first participant (13) . Second, the registration of not only the trial itself but also its details, especially its pre-designated primary outcomes, and eventually its results are now recommended. For example, as a result of the Food and Drug Administration Amendments Act of 2007 (FDAAA), not only registration but also submission of basic results is now mandatory for certain trials. Third, guidelines for fuller and more informative reporting of clinical trials have been published, required, updated, and expanded (14) (15) (16) (17) .
Unfortunately the more recent studies reveal that these human efforts have been only partially successful. Despite the advances in trial registration, quality of registered information is terms of timing and completeness is still not adequate (18, 19) . For example, a cross-sectional survey of clinical trial registries revealed that 36% of a sample of 100 registry records did not even specify measurement of primary outcomes. (18) . Another study showed fewer than 50% of trials were registered before the study start day (19) . With regard to reporting of trials, a comprehensive review has concluded that endorsement of the CONSORT statement may have had beneficial influence on the completeness of reporting, which however still remained sub-optimal (20) . A recent systematic review concluded 40-62% of studies had primary outcome discrepancies between the protocols and published reports (21) .
It is now increasingly recognized that the extent and magnitude of publication and related biases may be different for different types of studies and for different clinical disciplines (22, 23 Unfortunately, these two studies fall short of being able to characterize the current state of trial registration and outcome reporting in the field of psychiatry. First, both studies were conducted only a few years after the ICMJE requirement for trial registration (they studied trials published between 2007 and 2009) and may have been too early to detect its influence. Second, both studies included only top journals, and thus the prevalence of adequate registration and outcome reporting bias in the field of psychiatry at large remains unknown. Third, both of these studies combined trials involving a wide range of interventions together for analysis. In this respect, while they can probably be said to represent the average situation in the selected journals, neither study had enough statistical power to examine variations within the field in a differential manner. For example, adequate registration has been pointed out to be rare in non-drug trials (26) but it was impossible to examine such an influence in these two reviews.
The contrast between pharmacological and psychological interventions may be particularly pertinent to psychiatry. In drug trials publication bias has often been discussed in association with funding sponsors (5, 27) . On the other hand, in psychotherapy trials, the existence of publication bias has also been reported (28, 29) , but researchers' interests and allegiance appear to play a major role (28) . Additionally, quality of trials and quality of their reporting may be a bigger problem in psychotherapy trials than in pharmacotherapy trials (30, 31) .
To the best of our knowledge, no study to date has investigated trial registration and outcome reporting bias among drug and psychotherapy trials. Given the potential influences of the target clinical conditions on the quality of trials in the area, it is also important to focus on the same mental illness in order to appreciate the possible differences between the two types of interventions. We chose depression for assessment because it is one of the common mental illnesses and many trial reports have been published. We also decided to focus on two interventions cognitive behavioral therapy 
Aims of the study
The present study aims to investigate the proportion of depression trials that were properly registered and reported their primary outcomes in publications in the manner specified in the protocols or registry. We focused on cognitive behavioral therapy and new generation antidepressants trials for depression because depression is a common mental illness and antidepressants and cognitive behavioral therapy are well-established treatments that are representative of pharmacotherapy and psychotherapy for depression. We also aim to examine predictors of proper registration and reporting.
Material and Methods
The study protocol has been made available electronically on our homepage (http://ebmh.med.kyoto-u.ac.jp/r-ebm.html) (uploaded in January 2014). A diagnosis of depression should be made using operationalized diagnostic criteria or a validated depression symptom questionnaire. Trials that studied specific symptoms related to depression (e.g., insomnia in patients with depression) or comorbidities (e.g., abstinence in people with depression and alcohol dependence) were included. Trials that required more than two years from the start of patient enrollment until the assessment of the primary outcomes were excluded because such studies would require a longer time for implementation and reporting than other types of studies, and periods of less than 5
Study selection
years since the ICMJE statement may be too short to evaluate such studies properly.
Eligible interventions consisted of CBT based on the cognitive-behavioral model and the following new generation ADs: agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine, and vilazodone. We included trials that compared CBT and AD with other interventions but did not include those that used CBT or AD only as a control. Trials with both CBT and AD as intervention arms and those that studied collaborative care or augmentation therapies were included. However, they were excluded when we made comparisons between CBT and AD.
One investigator (KS) screened titles and abstracts and another author (AT, HI, NT, YH) reassessed the excluded studies. Any disagreement about inclusion of trials was resolved through discussion or in consultation with a third author (TF).
Data extraction
We used information in a trial report to retrieve its protocol or registry entry. When such information was missing, we sent e-mails to the corresponding authors at least twice at one week interval and with a wait for another two weeks for response. If no response from the authors was received, the trial was classified as "not registered".
From the published reports and trial registries, we next extracted the following information. If a trial report did not explicitly declare its primary outcome as "primary" or "main outcome", we selected the outcome used for the sample size calculation. When a trial neither identified its primary outcome nor provided sample size estimation, the trial was considered as a "trial without a declared primary outcome". If the timing of the report differed between the registry and the publication, we contacted the authors for further information.
Definition of proper registration and reporting
We examined the following three levels of proper registration and reporting. First, we assessed whether the trial was registered in a registry. Second, we defined trials as "properly registered" if they were registered before patient enrollment with specified primary outcomes. In our definition, a trial having specified primary outcomes should contain information explaining how the primary outcomes were measured. We also checked whether a trial had a fully specified primary outcome, that is whether it provided enough information to prevent a post-hoc choice regarding the method of aggregation including a specific measurement, specific metric, and method of aggregation (e.g., the mean change on the Hamilton Rating Scale for Depression (HAM-D)) (18) .
Third, among "properly registered trials", we checked the primary outcomes in published reports as specified in the registry. If the primary outcomes in the trial reports were the same as those in the registry entities, we classified them as "properly registered and reported" trials. There were two types of trials classified as "properly registered"
but not "properly registered and reported". The first type consisted of trials with any primary outcome discrepancy that met the following pre-specified criteria (34) . The second type consisted of trials that did not declare the primary outcomes in the publication, although they had specified them in the registry. We also judged whether the authors changed the primary outcomes to emphasize statistically significant result, with consideration given to the authors' intentions. If the publication contained more than one primary outcome, we chose the one that was mentioned first in the text.
Two authors (KS, AT, HI, NT, YH) performed all the data extractions and evaluations independently. Any disagreements during data extraction or evaluation discrepancies were resolved through discussions between the two reviewers or by consultation with a third author (TF).
Analyses
Our outcomes were the proportions of registered trials, properly registered trials, and "properly registered and reported" trials (our primary outcome) relative to all the included trials. Other outcomes included the number of trials that changed their primary outcomes so as to favor statistically significant results and those that were properly registered with fully specified and reported primary outcomes. We conducted two sensitivity analyses (limited to trials using operationalized diagnostic criteria and trials focusing on the acute phase of depression).
To identify factors that may contribute to proper registration and reporting, we compared the proportions of "properly registered and reported" CBT and AD trials and calculated the risk ratio for CBT vs. AD. We also examined whether the following pre-specified factors (24-26) may have influenced proper registration and reporting: publication in high impact factor (IF) journals, the region in which the study was conducted, the number of study centers, the number of arms, the funding source, the use of a published protocol, focus on a physical comorbidity (including pregnancy), and the sample size. We defined high IF journals as journals with the top ten impact factors in general medicine and similar impact factors in psychiatry and psychology, based on the Journal Citation Report for 2012.
We tested the associations between the factors and proper registration and reporting using Fisher's exact test for categorical data and Mann-Whitney U test for continuous data. The statistical tests were performed using SPSS statistics 22. The level of significance was set at the conventional p < 0.05 (two-tailed). For statistically significant factors, we conducted multiple logistic regression by entering all influencing factors at the same time to adjust for their mutual correlations.
Changes from the protocol
We were unable to conduct some subgroup analyses that we had pre-specified in our protocol: The number of primary outcomes in publication, trials with statistically significant primary outcomes, and endorsement of ICMJE by each journal. These and other minor changes are listed in the revised protocol on our home page.
Results

Study selection
A total of 2822 published reports were identified through the CENTRAL search (Fig. 1), and 642 full-text reports were assessed for eligibility. One hundred and sixty-nine published reports met our inclusion criteria: one report contained two trials based on the same design. All in all, 170 trials were included in our analysis. Table 1 "Registered" trials Eight trials had published protocols, but only one trial (35) had published its protocol before the study start day. Although 81 trials had a registry number in the published reports, the registry of one study (36) could not be accessed. Using information obtained from the authors, we found that 92 trials (54.1%) had been registered, 27 trials (15.9%) had not been registered, and the remaining 51 trials (30.0%) contained no information regarding registration. Therefore, we classified 92 trials as "registered". The three most commonly registered sites were Clinialtrials.gov (n = 53), ISRCTN.org (n = 13), and Iranian Registry of Clinical Trials (n = 10).
Characteristics of trials
"Properly registered" trials
Among the 92 registered trials, the timing of the registration was as follows: before trial commencement (n = 51), while the trial was in progress (n = 26), after the end of the trial (n = 13), and unclear (n = 2). All the registered trials had filled in their primary outcomes in the registry, but two trials (37, 38) provided almost no practical information regarding their primary outcomes. Among the remaining trials, 73 trials had specified measurement for their primary outcomes. Altogether, 43 trials (25.3% of 170 trials) were "properly registered" (i.e., registered before patient enrollment with specified primary outcomes). Of the properly registered trials, 19 trials registered fully specified primary outcomes.
"Properly registered and reported" trials
Among the 43 properly registered trials, 11 trials did not report their primary outcomes according to their registry entries: One trials did not declare their primary outcomes in the publication, although they had specified them in the registry. Ten trials had the following types of discrepancies in their primary outcomes: i) Registered primary outcome omitted in text (n = 4), ii) New primary outcome introduced (n = 2), iii) Different timing of assessment (n = 0), iv) Published primary outcome described as secondary in registry (n = 2), and v) Registered primary outcome reported as secondary outcome in text (n = 4).
Four trials had discrepancies favoring statistically significant results. The direction of the change was unclear in three trials because they omitted the original primary outcomes in the publication. None of the trials provided an explanation as to why they changed their primary outcomes in the publications.
Altogether, of all the included trials (n = 170), 18.8% (n = 32) were properly registered and reported (Table 2 ). Among them, 15 trials were properly registered with fully specified primary outcomes and were properly reported.
Factors influencing proper registration and reporting
Registration and proper registration were less common among CBT trials than among AD trials (Table 2) . Similarly, CBT trials were less frequently "properly registered and reported" than AD trials, although the difference did not reach statistical significance (risk ratio [RR], 0.51; 95% CI, 0.25 to 1.03) ( Table 2 ). In the two preplanned sensitivity analyses (limited to trials using operationalized diagnostic criteria and trials focusing on the acute phase of depression), the results did not change. Table 3 shows the results of subgroup analyses. We found associations between proper registration and reporting and the following factors: publication in high IF journals, the region in which the study was conducted, the number of study centers, the funding source, the use of a published protocol, and the sample size. However, it must be emphasized that among the 18 trial reports published in high IF journals, 10 trials (55.6%) were not "properly registered and reported".
To control for possible correlations among these factors, we conducted an exploratory per 100 persons, 95% CI: 1.00 to 1.65).
Discussion
In the present study, we examined reports of CBT and AD trials for depression to evaluate the prevalence of trial registration and selective outcome reporting in the field of psychiatry. First, we were able to confirm the proper registration and reporting of the primary outcomes in only 18.8% of the trials. Other trials were either not registered properly or did not report their primary outcomes according to their registry. Second, comparing interventions, the CBT trials were less likely to be properly registered and reported than the AD trials. Third, we identified some factors associated with proper registration and reporting, such as having a published protocol, being published in a high IF journal, and being a multinational or multicenter trial.
Proportions of "registered", "properly registered" and "properly registered and reported" trials Although our results cannot be easily compared with those of earlier studies because the proportions of the different trial categories would differ depending on the target cohorts of the trials and the definition of "proper registration", our results suggested that the quality and quantity of registration and the reporting of depression trials were poorer than general medicine trials but might be better than those of other medical specialty fields. Recent systematic reviews (39, 40) have identified some trials comparing registry entities and publications with the goal of assessing selective outcome reporting (34, 41) .
The percentage of registration appears to be lower in psychiatry than in general medicine (34) . On the other hand, the proportion of proper registration among the registered trials was higher for depression trials than for other medical specialties: e.g., only 5 out of 51 registered trials in top surgery journals (41) , and only 5 out of 67 in physical therapy trials (26) .
Within the field of psychiatry, our findings suggest that the situation seems to be better than previously reported. Milette et al. (25) reported that among 63 trials in top journals, 
Factors influencing proper registration and reporting
Although the difference did not reach nominal statistical significance, CBT trials tended to be less properly conducted in terms of registration and reporting. In other words, the relative risk of 0.51 (95% CI: 0.25 to 1.03) indicated that published AD trials were at least equally registered and properly reported and were possibly registered and properly reported four times more frequently than CBT trials. However, the results showed that other factors had a greater influence on proper registration and reporting than interventions.
Factors identified as influencing proper registration and reporting in this study were mostly consistent with previous reports (26, 42) . Although previous reports resulted in conflicting findings on the effect of funding on selective outcome reporting (43, 44) , the present study showed that commercial trials were properly registered and reported more frequently.
As the results of multiple logistic regression suggested, these influencing factors were related to each other. Trials with large sample size were often multinational or multicenter and received commercial funding. And they were required to be conducted in accordance with the guidelines (i.e. by publishing the protocol and being properly registered) so that they were more likely to be published in a high IF journal.
Limitation and strength
The present study has several limitations. First, we could not uncover post-hoc changes in the primary outcomes at deeper than the pre-specified levels. For example, if a trial only registered measurement (e.g. HAM-D) at registry, we could not detect post hoc changes of metric or aggregation for assessing their primary outcomes (e.g. from mean change on HAM-D to response rate using HAM-D). Second, this study only reviewed published trials, and our results are therefore not immune from study publication bias.
Future studies should use a prospective method to assess publication bias and selective outcome reporting bias simultaneously. The strong points of our study were that this is the first systematic and comprehensive survey of outcome reporting bias in psychiatry.
Our research suggested that, unfortunately, the requirements by ICMJE or by the reporting guidelines have not lead to enough improvement in registration and outcome reporting in psychiatry. However, this incompleteness did not always appear to be due to the author's intention to manipulate the results in their favor. Lack of awareness on the part of the authors and the complicated process of registration may be another cause of this problem. To overcome this problem, we suggest the following. First, systematic check of registration for each trial by the journal editors should improve adherence to these guidelines. Second, creating a more user-friendly interface for the registry site may be useful to prevent inadequate registration such as lack of detailed information of primary outcomes.
In summary, five years after the ICMJE requirement, almost half of published depression trials were not registered and another quarter of trials were registered but did not properly report the timing or other details. We could confirm the absence of selective outcome reporting of the primary outcomes in only 20% of the published reports. Researchers should disclose their planned primary outcome at the time of registry or should publish the protocol before they start the trial. Readers of medical literature should not assume that selective outcome reporting is not present, even if the report has been published in a high impact factor journal. 
